Merck & Co New: (NYSE: MRK)

$47.75

-0.05 (-0.11%)

Volume 11,626,578

Jun 18 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		47.66 - 48.05
	
		52wk Low - High
		38.72 - 50.16
	
		Previous Close
		47.80
	
		Avg. Volume
		26,470,430
	
		Industry
		LARGE CAP PHARMA
	
		Market Cap
		144.34 B
	
		Div - Yield
		1.72 - 3.60
	
		Beta
		0.59
	
		P/E (F1)
		13.68
	
		Current Year Est.
		3.49
	
		Quarterly Earnings ESP 
		2.41%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		178 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/2/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            13.68
                        
                            PEG Ratio
                            4.65
                        
                            Current Year Est.
                            3.49
                        
                            Current Quarter Estimate
                            0.83
                        
                            Most Accurate Estimate
                            0.85
                        
                            Earnings ESP 
                            2.41%
                        
                            Next Earnings Report Date
                            07-26-2013
                        
                            EPS Last Year
                            3.68
                        
                            Expected Earnings Growth
                            2.94%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.   
Full MRK Company Report

 Analyst Report on MRK

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
MRK Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.83	0.91	3.49	3.76
Number of Estimates	8	7	12	11
Low Estimate	0.80	0.87	3.44	3.64
High Estimate	0.87	0.95	3.56	NA
Year Ago EPS	1.05	0.95	3.82	3.49
EPS Growth	-20.48%	-4.36%	-8.53%	7.61%

More MRK Estimates

Average Earnings Estimates for MRK

EPS Growth for MRK

Industry Analysis

Name	Symbol	Previous Close
MERCK & CO INC	MRK	47.80
NOVO-NORDISK AS	NVO	161.70
ABBOTT LABS	ABT	36.89
ABBVIE INC	ABBV	43.01
ALLERGAN INC	AGN	101.48
ASTRAZENECA PLC	AZN	50.97
BRISTOL-MYERS	BMY	46.44
GLAXOSMITHKLINE	GSK	52.74
JOHNSON & JOHNS	JNJ	85.63
LILLY ELI & CO	LLY	52.36

Sector:Medical>> Industry:LARGE CAP PHARMA

COMPARE TICKER vs. Its Peers

Zacks Commentary

Luminex Collaborates with NMTC

Jun 14, 2013

Stock Market News for June 3, 2013

Jun 03, 2013

Data on Merck Candidate at ASCO

Jun 03, 2013

Orphan Drug Status for Astellas' Candidate

May 30, 2013

Stocks Market News for May 30, 2013

May 30, 2013

Mixed News on Merck's Pipeline

May 28, 2013

Merck Enters into Strategic Deal

May 22, 2013

Stock Market News for May 22, 2013

May 22, 2013

More MRK Zacks Commentary

Financials

EPS TTM	3.68
Sales	47,267
Net Income	6,516
Price/Earnings	12.99
Price/Book	2.60
Price/Cash Flow	7.77
Price/Sales	3.12

More MRK Financials

News

1,064 Cases Pending in the Fosamax Multidistrict Litigation: Now, AttorneyOne Can Provide Advice - Prweb

Jun 18, 2013

Global Kidney Cancer Drugs Market 2013 Report - M2

Jun 18, 2013

InSite Vision to jointly file patent infringement lawsuit against Mylan Pharmaceuticals along with Merck - M2

Jun 18, 2013

IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product - Globenewswire

Jun 18, 2013

Interesting Similarities Among 2013`s Top-Performing ETFs - Benzinga

Jun 18, 2013

John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations - Pr Newswire

Jun 18, 2013

Market Maker Surveillance Report. ESSE, MRK, CPST, LYG, MPG, FTR, Highest Net Sell Volume and Negative Price Friction For Monday, June 17th 2013 - M2

Jun 18, 2013

Medivo raises $15 million in Series B financing round - Datamonitor Financial Deals Tracker

Jun 18, 2013

See All News Stories on MRK

Broker Recommendations

Current ABR	1.83
ABR (Last Week)	1.83
# of recs in ABR	16
Average Target Price	50.79
Industry Rank by ABR	178 out of 265
Rank in Industry	2 out of 15

More MRK Broker Recommendations

Day Low - High	47.66 - 48.05
52wk Low - High	38.72 - 50.16
Previous Close	47.80
Avg. Volume	26,470,430
Industry	LARGE CAP PHARMA
Market Cap	144.34 B
Div - Yield	1.72 - 3.60
Beta	0.59
P/E (F1)	13.68
Current Year Est.	3.49
Quarterly Earnings ESP	2.41%

P/E (F1)	13.68
PEG Ratio	4.65
Current Year Est.	3.49
Current Quarter Estimate	0.83
Most Accurate Estimate	0.85
Earnings ESP	2.41%
Next Earnings Report Date	07-26-2013
EPS Last Year	3.68
Expected Earnings Growth	2.94%

Username: Password:

Remember me [?]

Merck & Co New: (NYSE: MRK)

$47.75

-0.05 (-0.11%)

Volume 11,626,578

Jun 18 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:LARGE CAP PHARMA

Zacks Commentary

Financials

News

Broker Recommendations